Bio-Techne Corp (TECH)
NASDAQ: TECHHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TECH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $11.42B
- P/E (TTM)
- 66.67
- Forward P/E
- 31.43
- EPS (TTM)
- $1.09
- Dividend yield
- 0.33% ($0.24)
- Ex-dividend date
- Nov 13, 2026
- 52-week range
- 43.20 – 72.88
- Day range
- 72.66 – 72.77
- Volume / Avg
- 3.66M / 2.91M
- Beta
- —
- Shares outstanding
- 157.09M
52-week range
TECH stock today
Shares of Bio-Techne (TECH) finished lower on Nov 20 at $72.67, a drop of 0.04% or $0.03 per share, versus the S&P 500's 3.70% decline. The stock is trading at or near its 52-week high of $72.88, set on Nov 9, 2026, 68.2% above the 52-week low of $43.20. TECH is up 23.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 18.1%.
At 66.7x trailing earnings, Bio-Techne trades above the peer-group median of 24.7x. Its forward P/E of 31.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Bio-Techne pays an annual dividend of $0.24 per share, a 0.33% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Bio-Techne
Company profileBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Kim Kelderman
- Headquarters
- Minneapolis, MN
- Employees
- 3,000
- Website
- bio-techne.com
Financial highlights
Full financialsIn fiscal 2026, Bio-Techne generated $1.22 billion in revenue, down 0.4% from fiscal 2025, its first annual decline since 2013. Net income was $181.9 million (+147.8% year over year), for a net margin of 15.0% versus a median of 15.1% in the prior 5 years. Gross margin was 65.8% (up from 64.8%) and operating margin 20.7%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $1.22B | $1.22B | $1.16B | $1.14B | $1.11B |
| Growth | -0.38% | +5.23% | +1.97% | +2.81% | +18.75% |
| Net income | $181.86M | $73.40M | $168.10M | $285.26M | $272.05M |
| EPS (diluted) | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 |
Analyst forecast
ForecastConsensus (13 analysts)
hold
Avg. price target
$70.50-2.99%
- Strong buy 0
- Buy 0
- Hold 12
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $0.36 vs $0.40
- Surprise
- -10.00%
Dividends
Dividend history- Annual dividend
- $0.24
- Dividend yield
- 0.33%
- Last payment
- $0.08
- Ex-dividend date
- Nov 13, 2026
- Pay date
- Nov 23, 2026
TECH news
All TECH news- CorMedix (CRMD) Reports Q3 Loss, Tops Revenue EstimatesNasdaqCRMD, TECH
- Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue EstimatesNasdaqHUMA, TECH
- TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal AdvancesNasdaqTECH, ISRG, MEDP, GEHC
- Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue EstimatesNasdaqROIV, TECH
- Bio-Techne Q1 Profit DownNasdaq
- Bio-Techne Corporation Declares Quarterly Dividend of $0.08 Per ShareNasdaqTECH, WSO.B
- Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue EstimatesNasdaqRYTM, TECH
- CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue EstimatesNasdaqCRSP, TECH
Bio-Techne peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RGENRepligen Corporation | 163.81 | -3.81% | $10.47B | vs TECH |
| HALOHalozyme Therapeutics Inc. | 91.35 | -1.82% | $10.41B | vs TECH |
| QGENQiagen N.V. | 49.30 | -0.66% | $10.18B | vs TECH |
| KYMRKymera Therapeutics Inc. | 115.31 | -3.42% | $9.84B | vs TECH |
| KRYSKrystal Biotech Inc. | 308.89 | -2.19% | $9.15B | vs TECH |
| PCVXVaxcyte Inc. | 55.39 | -5.09% | $8.77B | vs TECH |
| NBIXNeurocrine Biosciences Inc. | 150.57 | -3.84% | $15.24B | vs TECH |
| CGONCG Oncology Inc. | 79.47 | -2.97% | $7.10B | vs TECH |
Indexes, lists and sector
Bio-Techne stock FAQ
What is Bio-Techne's stock price today?
TECH last traded at $72.67 as of Nov 20, 4:00 PM EST, down 0.04% on the day. Prices are delayed at least 15 minutes.
Does Bio-Techne pay a dividend?
Yes. Bio-Techne pays $0.24 per share annually, a 0.33% yield. The most recent dividend of $0.08 had an ex-dividend date of Nov 13, 2026.
What is TECH's P/E ratio?
TECH trades at a trailing P/E ratio of 66.67 and a forward P/E of 31.43, compared with a median of 24.7 for its closest peers.
Is Bio-Techne in the S&P 500?
Yes. Bio-Techne (TECH) is a constituent of the S&P 500 index.
Who is Bio-Techne's CEO?
Mr. Kim Kelderman is the chief executive officer of Bio-Techne Corp, which has about 3,000 employees.
Has TECH ever split its stock?
Yes. The most recent TECH stock split was a 4-for-1 split on Nov 30, 2022, one of 3 splits on record.
What is the TECH 52-week high?
The 52-week high for TECH is $72.88 and the 52-week low is $43.20. The stock is currently 0.3% below its high.